Fulgent Genetics Schedules Annual Meeting, Proposes New 2026 Equity Incentive Plan
FLGT sits 18% above its 52-week low of $13.46.
Summary
Fulgent Genetics, Inc. has filed definitive additional proxy materials for its upcoming annual meeting, where stockholders will vote on the election of directors, auditor ratification, executive compensation, and a new 2026 Equity Incentive Plan.
Key Events · Corporate Governance and Compliance · FLGT
-
Annual Meeting Scheduled
Fulgent Genetics will hold its 2026 Annual Meeting of Stockholders on Thursday, May 14, 2026.
-
New Equity Incentive Plan Proposed
Stockholders will vote on the approval of a new 2026 Equity Incentive Plan, which could lead to future share dilution if approved.
-
Routine Governance Items
Other proposals include the election of four directors, ratification of Deloitte & Touche LLP as the independent auditor, and an advisory vote on executive compensation.
Analysis · FLGT · Industrial Applications And Services
This DEFA14A serves as a notice for Fulgent Genetics' 2026 Annual Meeting of Stockholders. While most items are routine, the proposal to approve a new 2026 Equity Incentive Plan is notable. This plan, if approved, will authorize additional shares for employee compensation, leading to future dilution for existing shareholders. This comes at a time when the company has reported increased net losses and a significant expected revenue decline, making any potential dilution a more sensitive issue for investors.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 30% of the 1759 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FLGT was trading at $15.90 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $496.6M. The 52-week trading range was $13.46 to $31.04. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.